Personalized medicine company Genomind names CEO & president
Source, Philadelphia Business Journal, John George
Genomind, a personalized medicine company, has revamped its leadership team with the appointment of a new CEO and a new president.
Founded in 2009, Genomind of King of Prussia is the developer of a genetic test, the Genecept Assay, used to help clinicians make treatment decisions for their patients with mental illness. The assay indicates what medications are likely to be the most effective based on a patient’s genetic profile. The company also recently introduced its Mindful DNA genetic test that provides “evidence-based, personalized, actionable information that helps patients adjust their lifestyle, diet, habits and activities to improve their overall quality of life.”
Genomind hired Shawn Patrick O’Brien as CEO. O’Brien was most recently chairman of Key BioPharma Partners, a private biopharma consulting firm he founded.
He succeeds Michael Koffler, who left the company this summer to become president and CEO of FSSolutions, a Chalfont-based third-party administrator of drug and alcohol testing programs.
Prior to Key BioPharma, O’Brien served as president and CEO of Cipher Pharmaceuticals Inc., AltheRx Pharmaceuticals Inc., Profectus BioSciences Inc. and Solstice NeuroSciences Inc. Earlier in his career O’Brien held multiple senior leadership roles within AstraZeneca.
O’Brien was attracted the company because of its “stellar reputation for delivering actionable insights” to clinicians, health care partners, and individuals to improve the quality of mental health. “This is an exciting time in the field of pharmacogenetics, and I know everyone on the Genomind team is looking forward to growing the impact of our important work,” he said.
Genomind also named Kip Olmstead as president, a title also previously held by Koffler. Olmstead held consumer packaged goods and health care marketing roles in senior leadership positions at First Quality Enterprises, Crayola, and Procter and Gamble, where he worked brands like Prilosec OTC, Oral-B, Duracell, and Prevail.
Additionally, Genomind promoted David Robbins to chief scientific officer. Robbins previously served as the company’s senior vice president of molecular pathology and laboratory director. Prior to joining Genomind, he founded the nucleic acids testing division of UTC Labs. He also held posts at SmithKline Clinical Labs, now Quest Diagnostics, and Abbott Labs.
Thomas Hess, who had been serving as Genomind’s interim CEO as well as its chief financial officer, will return to his full time duties as CFO.